Contract research organization signs agreement to utilize NewCardio's QTinno(TM) software suite

Aug 27 2009

NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that a top-three contract research organization has signed a Master Services Agreement (MSA) to use NewCardio's QTinno(TM) software suite as its technology in fully automated Thorough QT (TQT) and Phase 1 studies delivered by its centralized ECG core lab. NewCardio expects to collaborate on the first fully automated study, tentatively scheduled to begin during the third quarter of 2009, and it is anticipated that the customer will increasingly deliver fully automated results through QTinno(TM) in TQT/QT studies going forward.

"NewCardio is pleased to announce its second MSA, with a leading contract research organization, which represents another significant milestone in the industry adoption of QTinno(TM), our automated cardiac safety solution," said Vincent Renz, NewCardio's President and Chief Operating Officer. "We look forward to working closely with them to rapidly implement our validated solution in order to meet their growing demand for fully automated trials. The agreement will enable them to deliver exactly what their customers are asking for: high-quality TQT/QT studies, which will minimize the risk of false positives or false negatives, all delivered in a more timely and more cost-effective manner than the current core lab methodologies allow."

NewCardio's innovative 3D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12-lead electrocardiogram (ECG). NewCardio's lead product is QTinno(TM), a software suite that provides an automated, comprehensive analysis of QT intervals and other ECG-based cardiac safety for the pharmaceutical industry and drug regulators. The Company believes that its QTinno(TM), software-based, analytical technology is the industry's first solution for the reliable automated analysis of ECGs used to determine cardiac toxicity during drug development.